Article Versions Notes

Chou H-W, Cheng K-P, Lin A-C, Hung H-C, Lin C-H, Wang C-C, Wu H-T, Ou H-Y. Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin. Pharmaceuticals. 2022; 15(12):1569. https://doi.org/10.3390/ph15121569

Chou, Hsuan-Wen, Kai-Pi Cheng, An-Chi Lin, Hao-Chang Hung, Ching-Han Lin, Chih-Chen Wang, Hung-Tsung Wu, and Horng-Yih Ou. 2022. "Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin" Pharmaceuticals 15, no. 12: 1569. https://doi.org/10.3390/ph15121569

Chou, H. -W., Cheng, K. -P., Lin, A. -C., Hung, H. -C., Lin, C. -H., Wang, C. -C., Wu, H. -T., & Ou, H. -Y. (2022). Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin. Pharmaceuticals, 15(12), 1569. https://doi.org/10.3390/ph15121569